Sucampo Pharmaceuticals, Inc. and Revolution Lighting Technologies News: (NASDAQ:SCMP), (NASDAQ:RVLT)
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) and Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Sucampo’s supplemental new drug application (sNDA) for AMITIZA® (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain.
View full press release